BioAtla, Inc. (BCAB) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BCAB Revenue Growth
BCAB Revenue Analysis (2018–2025)
As of May 8, 2026, BioAtla, Inc. (BCAB) generated trailing twelve-month (TTM) revenue of $2.0 million. The most recent quarter (Q4 2025) recorded $2.0 million in revenue.
Looking at the longer-term picture, BCAB's 5-year compound annual growth rate (CAGR) stands at +36.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $11.0 million in 2024.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), AGEN (+10.4% YoY), and MGNX (+0.8% YoY). Compare BCAB vs RCUS →
BCAB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BCABCurrent | $2M | - | +36.1% | -2965.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 MGNX | $150M | +0.8% | +8.9% | -48.7% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% |
BCAB Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.0M | -81.8% | $2.0M | 100.0% | $-59,305,000 | -2965.3% |
| 2024 | $11.0M | - | $10.1M | 91.6% | $-73,943,000 | -672.2% |
| 2023 | $0 | - | $-1,221,000 | - | $-129,687,000 | - |
| 2022 | $0 | -100.0% | $-1,199,000 | - | $-108,140,000 | - |
| 2021 | $250K | -41.7% | $250K | 100.0% | $-96,440,000 | -38576.0% |
| 2020 | $429K | -91.8% | $-19,504,000 | -4546.4% | $-30,099,000 | -7016.1% |
| 2019 | $5.2M | -51.1% | $-20,719,000 | -398.4% | $-28,268,000 | -543.6% |
| 2018 | $10.6M | - | $-15,678,000 | -147.5% | $-28,234,000 | -265.7% |
See BCAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCAB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCAB — Frequently Asked Questions
Quick answers to the most common questions about buying BCAB stock.
Is BCAB's revenue growth accelerating or slowing?
BCAB TTM revenue: $2M. YoY growth: N/A. 5-year CAGR: +36.1%.
What is BCAB's long-term revenue growth rate?
BioAtla, Inc.'s 5-year revenue CAGR of +36.1% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is BCAB's revenue distributed by segment?
BCAB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.